Table 4

Later-onset AEFI reported by AusVaxSafety participants following live attenuated herpes zoster vaccine by sex and underlying medical condition (final survey)*

Males
n (%)
Females
n (%)
RR (95% CI) (females vs males)No medical condition
n (%)
Medical condition
n (%)
RR (95% CI) (medical condition vs no condition)
Influenza-like Illness10 (6.2)22 (11.7)1.88 (0.92 to 3.86)17 (8.6)15 (9.9)1.16 (0.60 to 2.24)
Chickenpox-like rash1 (0.6)7 (3.7)5.99 (0.75 to 48.2)4 (2.0)4 (2.6)1.31 (0.33 to 5.16)
Hospitalisation †1 (0.6)1 (0.5)0.86 (0.05 to 13.64)2 (1.0)0 (0.0)NA
  • *Denominator includes Vaxtracker participants responding to a final opt-in survey by SMS or email sent 24 days following vaccination (M: 161, F: 188, total: 349). Of these, 151 had an underlying medical condition.

  • †Hospitalisation for allergic reaction (one following a dental procedure and one following consumption of shellfish).

  • AEFI, adverse events following immunisation; NA, not available; SMS, short message service.